Sandwich, Kent, UK, 17th January 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces an investment of £100K into Vox Imaging Technology Ltd. (VIT), an ambitious ophthalmic technology company looking to transform eye imaging in preclinical research and improve drug discovery and development. Its compact and customisable instrument is believed to be the first scanning laser ophthalmoscope especially designed for laboratory use, able to produce high-quality data rapidly. Vox Imaging is the eighth investment from DPV’s first fund.
As the life sciences sector continues to evolve at a rapid pace, Biocair, a leading global life science logistics expert, stands at the forefront of industry excellence and customer service. Manish Joshi, Biocair’s Chief Commercial Officer, gives us insight into how Biocair is staying ahead of trends that will shape the industry in 2024.
Sustainability revolutionizing the life sciences supply chain
Enter our competition for a chance to win a place on a concentrated three-day bootcamp in Boston with boardroom-style sessions, led by top life science businesses in the Greater Boston cluster, aimed at providing a focused ‘Getting US-ready’ experience. Whether you are looking to enter the US market for investment, collaborations or clients, this is a brilliant opportunity to embark on a journey to elevate your business to the next level.
CELLBANKER® freezing media from AMSBIO is now available in customizable formats, seamlessly integrating into cell manufacturing processes with personalized formulations, volumes, and packaging.
Cited in over 500 scientific publications, the CELLBANKER range has proven itself as a safe and reliable solution for storing cells and tissues. This includes GMP-grade, chemically defined formulations specifically designed for the storage of biospecimens for clinical applications.
• Sentiment among UK CFOs has risen for the second consecutive quarter, with optimism running well above average levels;
• Inflation and high interest rates have dropped down the CFO risk list;1
• Corporate risk appetite has risen to an 18-month high but remains subdued relative to its long-term average;
• 63% of CFOs anticipate higher investment in new technology;
• CFOs believe geopolitical factors pose the greatest external risk to their own businesses over the next 12 months.
CAMBRIDGE, UK & BOSTON, US – JANUARY 2, 2024 – Apollo Therapeutics (“Apollo” or “the Company”), a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, today announces that during December 2023 it completed a second close of its Series C financing, raising an additional $33.5 million and bringing the total raised in this round by the Company during 2023 to $260 million.
ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION COLLABORATION
Cambridge, UK, 8 January 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the expansion of its ongoing, exclusive formulation study collaboration with the pharmaceutical division of one of the world’s largest chemicals marketing and pharmaceuticals companies, which focuses on the development and commercialisation of speciality drugs.
Happy new year to our fantastic members, partners, sponsors and collaborators.